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Debate article 25 
Title: Training in Multiple Breath Washout testing for respiratory physiotherapists 26 
 27 
Abstract: 146/200 28 
Introduction: The development of multiple breath washout (MBW) testing in respiratory 29 
disease highlights the need for increased awareness amongst respiratory physiotherapists and 30 
a potential opportunity for professional development in the use of an important outcome 31 
measure for clinical trials. 32 
Objectives: To rationalise how MBW may be a useful assessment tool for respiratory 33 
physiotherapists and to describe a local MBW training and certification programme for 34 
physiotherapists.   35 
Results: The respiratory Multi-Disciplinary Team in the Belfast Health and Social Care Trust 36 
(BHSCT) identified a need for MBW testing to be available to facilitate clinical research and 37 
assessment. A 2 day training programme consisting of pre-reading preparation, self-directed 38 
learning, theory presentations, practical demonstrations and hands-on practice was developed 39 
and delivered. All participants underwent a certification process. 40 
Conclusion: We have demonstrated the successful training and certification of clinical and 41 
research physiotherapists and encourage other respiratory physiotherapists to consider MBW 42 
test training. 43 
 44 
 45 
 46 
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 47 
Contribution of paper 48 
• This paper highlights the need for increased awareness amongst respiratory 49 
physiotherapists and a potential opportunity for professional development in the use of 50 
an important outcome measure for clinical trials. 51 
• This paper demonstrates that respiratory physiotherapists can obtain training and 52 
certification in MBW testing 53 
 54 
Keywords 55 
Respiratory physiotherapy; multiple breath washout testing; lung clearance index; training; 56 
eLearning. 57 
 58 
Introduction 59 
In recent years, there has been a resurgence of interest in multiple breath washout (MBW) 60 
testing in respiratory disease. This method has the advantage of improved sensitivity in the 61 
detection of early airways disease compared to spirometry and has improved feasibility across 62 
a wider age range, requiring only relaxed tidal breathing. Studies in Cystic Fibrosis (CF) have 63 
shown that measures of MBW detect early lung disease, relate to measures of spirometry and 64 
health related quality of life and are responsive to mucolytic therapies (1-7). Consequently, 65 
parameters of MBW have been recommended as outcome measures in clinical trials in CF (8) 66 
and have already been used in landmark CF trials (9,10). Research into MBW in other 67 
respiratory conditions have also demonstrated that it could be a useful tool to detect disease 68 
and measure treatment response (11-14). FEV1 is a key outcome measure in CF and is currently 69 
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the only Food and Drug Administration (FDA) approved surrogate outcome measure for use 70 
in clinical trials (15). It is also the most commonly used and reported measure of lung function 71 
in other lung diseases such as COPD (16). However, FEV1 has physiological limitations; it 72 
primarily reflects the larger airways rather than the more peripheral, smaller airways which 73 
make up the majority of the surface area of the lung and where early processes occur (17). 74 
Furthermore in CF, the slow rate of decline in FEV1 evident as a result of improved standards 75 
of care (18), limit its sensitivity to detect change in clinical status and response to treatment. 76 
Spirometry can only be reliably carried out in individuals aged >6 years as it requires ability to 77 
take instruction and co-operation. There is a clear need for an alternative measurement of lung 78 
function. As research has established that MBW is a valid and reliable measure of ventilation 79 
distribution which correlates with lung disease severity (8), it has become established as a 80 
secondary outcome in clinical trials and may also have a place in regular clinical monitoring in 81 
CF. Moreover, MBW could potentially inform physiotherapy assessment and the evaluation of 82 
new treatments. 83 
Unlike spirometry, MBW is not part of undergraduate training programmes and there 84 
are few training programmes outside specialist research centers. Therefore, in order to facilitate 85 
the translation of MBW into clinical care there is a need for effective training.  We propose 86 
that training respiratory physiotherapists to perform MBW could be advantageous in the 87 
management of respiratory patients.   88 
 89 
Objectives 90 
The objectives of this article are to 91 
1. Rationalise how MBW may be a useful assessment tool for respiratory physiotherapists. 92 
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2. Describe a local MBW training and certification programme for physiotherapists.   93 
3. Highlight available MBW training resources. 94 
 95 
MBW testing 96 
In respiratory disease, airway narrowing from mucus obstruction, inflammation and structural 97 
airway damage can cause uneven ventilation distribution and the degree of disease severity can 98 
be assessed using MBW. Lung Clearance Index (LCI) is the most commonly reported measure 99 
of the MBW test and represents the number of functional residual capacity (FRC) volume 100 
turnovers required to “washout” the tracer gas during testing. Individuals with uneven 101 
ventilation distribution use a greater number of turnovers to washout the tracer gas and 102 
therefore will have a higher (more abnormal) LCI. Although MBW tests have been available 103 
for many years, research and clinical interest has increased recently due to the availability of 104 
more sophisticated and user friendly equipment. The MBW test can be performed either with 105 
inhalation of an inert tracer gas such as sulphur hexafluoride (SF6) or helium (He), or by using 106 
100% oxygen (02) to wash out resident nitrogen (N2). When using SF6 or He, the gas is first 107 
washed into the lungs and then washed out. When using N2 washout, 100% 02 is delivered until 108 
N2 is washed out. The European Respiratory Society/American Thoracic Society (ERS/ATS) 109 
consensus statement for inert gas washout measurements (19) provides evidence based 110 
guidelines on equipment specifications, test performance and analysis of results and is a key 111 
reference document for sites planning the set-up and delivery of MBW testing. Some key points 112 
about MBW from the inert gas washout measurements consensus statement (19) and an 113 
evidence review for LCI (8) are summarized in Table 1.  114 
 115 
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 116 
 117 
Table 1: MBW key points  118 
 119 
 120 
 121 
 122 
 123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
There are key areas where LCI demonstrates potential clinical utility. Firstly, LCI can 132 
detect early lung disease, potentially informing clinical decisions on treatment and 133 
management plans earlier in the disease trajectory. It has been shown to detect early lung 134 
disease in children and adults and is more sensitive than measures of spirometry (FEV1) in both 135 
CF and bronchiectasis (2,5,11). Indices from the MBW test have also been shown to be 136 
sensitive to lung disease in asthma (13), COPD (14) and alpha-1-antitrypsin deficiency (20). 137 
 
• MBW tests assess the efficiency of ventilation distribution (19) 
• LCI is the most commonly reported MBW index in current paediatric and adult literature (19) 
• LCI is the number of functional residual capacity (FRC) lung volume turnovers required to 
reduce tracer gas concentration to a fraction of its starting concentration (19) 
• End of washout is historically defined as 1/40th of the starting tracer gas concentration (19) 
• MBW testing requires only tidal breathing and stability of resting lung volumes throughout the 
washout is critical (19) 
• LCI is reported as the mean (SD) of 3 technically acceptable and repeatable washout tests (19) 
• In a healthy person, upper limits of normal for LCI between 7.0 – 7.5 have been reported (2,30)  
• A complete MBW testing session (3 tests) typically lasts between 20 - 40 minutes (2,31) 
• The minimum clinically important difference in LCI has yet to be defined but treatment effects 
of 1.0-2.2 lung turnovers have been reported (3,9,32,33) 
• LCI is dependent on body size and appropriate reference equations are essential for accurate 
interpretation of results (34) 
• Results are specific to equipment and therefore are not comparable across different systems 
(e.g. system using SF6 vs. system using N2 as tracer gas)  
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Importantly, LCI relates to other meaningful clinical endpoints and patient centered 138 
outcomes, which confirms its validity as a useful measure. In CF, LCI has been shown to relate 139 
to health related quality of life as measured by a validated questionnaire, and to predict 140 
pulmonary exacerbations (4,21). In both CF and bronchiectasis, LCI relates to measures of 141 
high resolution computed tomography (HRCT) chest imaging (11). LCI has been shown to be 142 
responsive to the disease modulating therapy, ivacaftor, in CF (9). LCI, but not FEV1% 143 
predicted, was also responsive to mucoactive therapies including inhaled hypertonic saline (3) 144 
and DNase in CF (7). The responsiveness of LCI highlights that it could have a potential role 145 
in the assessment of therapies and in the long term monitoring in patients.  146 
A small number of studies have been carried out to investigate the short term effect of 147 
airways clearance interventions on LCI in both CF and bronchiectasis. In CF, one study 148 
demonstrated a significant reduction (improvement) in LCI following treatment with Non-149 
Invasive Ventilation compared to Positive Expiratory Pressure mask in 32 patients with CF 150 
(22). Measures of gas mixing efficiency from a single-breath gas washout test also improved 151 
significantly after airway clearance in 25 children with CF (23). The majority of studies show 152 
no change or a variable change (increase and decrease) in LCI (12,24-26). This highlights that 153 
airways clearance techniques cause alterations in gas mixing which are greater than those who 154 
do not undergo airway clearance. One theory suggested is that airway clearance may open up 155 
previously “blocked off” areas caused by mucus plugging, or relieve areas of atelectasis, 156 
opening up poorly ventilated areas, thereby causing a rise (worsening) in LCI. Further studies 157 
of the medium to long-term effect of airways clearance techniques on LCI and other MBW test 158 
outcomes would be beneficial in informing physiotherapists whether there is a place for MBW 159 
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testing in assessing airways clearance. The challenge with airways clearance trials remains that 160 
there is no consensus on the best index to use to measure effect (27). 161 
As MBW testing demonstrates utility across a range of respiratory diseases, both 162 
clinical and clinical trial sites are exploring the acquisition of equipment and training in order 163 
to embed this outcome measure in trials and to offer this test as part of their assessment. This 164 
highlights a development opportunity for respiratory physiotherapists. 165 
 166 
The role of respiratory physiotherapists 167 
Respiratory physiotherapists are directly involved in conducting and interpreting lung function 168 
tests and the key role of the physiotherapist in evaluating response to inhaled therapies, airways 169 
clearance therapies and physical activity has been highlighted in CF (28). Physiotherapists are 170 
ideally placed to build on their existing knowledge and expertise in acquiring the skill of MBW 171 
testing, which could potentially be utilized as part of their patient’s assessment. Respiratory 172 
physiotherapists form an integral part of the multidisciplinary team and are involved in the 173 
assessment of patients’ respiratory status within the context of outpatient appointments, annual 174 
assessments as well as inpatient admissions. MBW testing falls under the Chartered Society of 175 
Physiotherapy (CSP) scope of practice of physiotherapy in the UK, defined as “any activity 176 
undertaken by an individual physiotherapist that may be situated within the four pillars of 177 
physiotherapy practice where the individual is educated, trained and competent to perform that 178 
activity” (CSP, 2008) and therefore is covered under professional liability insurance. As MBW 179 
testing has its roots in clinical research, conduct of the technique has historically been the remit 180 
of the researcher. Implementing research practices into clinical practice is challenging and 181 
requires the collaboration and commitment of the academic researchers, clinicians, managers 182 
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and patients. Increasing awareness and knowledge of new assessments, skills required and the 183 
wider practical implications are recognised aspects of successful integration of change to 184 
practice (29). A key feature of all clinical practice including physiotherapy practice, is the 185 
capacity to respond and evolve to changes in healthcare. A focus on providing the training 186 
opportunities to support physiotherapists to be competent at embedding new techniques within 187 
their clinical practice will facilitate the translation of research into practice. To enable the 188 
successful integration into clinical practice, appropriate training in the technical aspects of set 189 
up, conducting the test, and interpretation and quality assurance of results is essential (19). 190 
Through our experience of delivering a training programme, we have demonstrated how both 191 
clinical and research physiotherapists can successfully complete training and certification in 192 
this skill for use in research and clinical practice.  193 
 194 
Training programme 195 
The respiratory Multi-Disciplinary Team in Belfast Health and Social Care Trust (BHSCT) 196 
identified a need for MBW testing to be available to facilitate clinical research and clinical 197 
assessment. In response to this, a 2 day programme was developed and delivered by a Queen’s 198 
University Belfast PhD researcher (physiotherapist KON) trained in using the modified 199 
Innocor™ device (by an external expert in the equipment, Dr Alex Horsley, University of 200 
Manchester). The programme consisted of pre-reading preparation, self-directed learning, a 201 
presentation on theory, practical demonstrations and practice. Thereafter to be certified, 202 
participants completed 10 tests after the 2 day programme which were then assessed for 203 
technical validity and repeatability. The trainer was available for trouble shooting on 204 
calibration and testing during the certification process. Table 2 details the programme content 205 
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and layout and the certification procedure. Appendix 1 details the programme in full. All 206 
content was based on the device Standard Operators Procedure (used with permission) 207 
“Multiple breath washout test using modified Innocor TM device SOP; UK Cystic Fibrosis Gene 208 
Therapy Consortium; September 2010, Dr. Nick Bell” and on guidance from external expert 209 
Dr Alex Horsley, University of Manchester. A knowledge (6 multiple choice questions) and 210 
confidence (Likert visual analogue scales rating setting up the equipment, conducting and 211 
interpreting the test) questionnaire was completed by participants before the programme and 212 
after submission of certification tests (appendix 2). Participants were also asked to make 213 
suggestions for improvement of the programme. 214 
 215 
Table 2: Programme content and layout 216 
Preparation:  
Key references and protocols for pre-reading. 
Day 1:  
Background to MBW. Overview of references and Standard Operating Procedure. 
Familiarisation with equipment components, on-screen menus and consumables. Overview 
and practice of calibrations. Patient preparation for testing. 
Day 2:  
Explanation and demonstration of phases of testing: Washin phase, beginning of washout, 
washout phase. Practice testing with volunteer and quality control of readings. Log keeping, 
cleaning of equipment and infection control. Accessing and downloading tests. 
Certification procedure:  
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Trouble shooting on calibration and testing. 
Collection of 10 tests.  
9/10 technically acceptable tests required for certification. 
If <9/10 tests valid, submission of additional 5 tests. 
 217 
The programme was delivered on 2 occasions to a total of 10 participants (5 clinical researchers 218 
[3 physiotherapists, 1 nurse, 1 clinical physiologist] and 5 clinical physiotherapists) based in 219 
BHSCT. All 10 participants completed the 2 day programme. However 2/10 participants 220 
(clinical physiotherapists) did not complete the certification procedure (no time due to clinical 221 
caseload). The remaining 8 participants successfully completed the certification procedure. Six 222 
participants completed the knowledge and confidence assessment before and after the 223 
programme and certification (2 participants did not complete the certification and 2 completed 224 
the programme before the knowledge and confidence questionnaire was introduced). For these 225 
6 participants, knowledge improved from 61% at baseline to 100% post programme. 226 
Confidence improved from 3% at baseline to 76% post programme; however 2 participants 227 
highlighted that they still were not very confident in interpreting MBW results. Suggestions for 228 
improvement included the development of eLearning material, the inclusion of content on N2 229 
washout devices and information on the interpretation and analysis of MBW results. 230 
Experience from this programme demonstrates how both clinical and research 231 
physiotherapists can successfully complete a training and certification programme in MBW 232 
testing. As 2 clinical staff members were unable to complete certification due to time 233 
constraints it highlights that agreement and ongoing support from management is required to 234 
ring fence time to organise and complete certification readings.   235 
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Resources for MBW training  236 
For those wishing to pursue training in MBW testing, the ERS/ATS inert gas washout 237 
consensus statement provides a comprehensive outline on all aspects of equipment 238 
specifications, test performance and analysis (19). As MBW testing involves practical and 239 
technical skills, face-to-face training for “hands-on” experience is considered optimal. During 240 
the equipment installation process manufacturers usually provide training according to their 241 
standard operating procedure. Additional training is required to obtain certification to a 242 
research quality standard and there are UK sites who provide training, certification and an over-243 
reading service (quality checking and final result verification of MBW data) as well as a point 244 
of contact for re-fresher training and troubleshooting. (Royal Brompton and Harefield Hospital, 245 
London and BHSCT). 246 
MBW testing is a developing area and is technically challenging to perform. Therefore, 247 
regular practice with quality control checks is essential to ensure that confidence and 248 
competence with use of the equipment is maintained.  Re-fresher training is important if time 249 
has elapsed since original training or last use. As MBW is primarily a research tool at present, 250 
it is possible that the operator may become deskilled if using the method infrequently or only 251 
during a specific clinical trial. eLearning tools are one method that reinforce face-to-face 252 
learning and support re-fresher training remotely. Some eLearning resources have been 253 
developed by commercial companies using MBW testing, however access is restricted to sites 254 
participating in the clinical trial. An eLearning tool developed at Queen’s University Belfast 255 
(www.MBWtraining.com), is open access and provides comprehensive information on MBW 256 
testing using a variety of learning mediums including slideshow presentations, animations and 257 
a step by step library of videos demonstrating set-up and testing. The tool also includes a self-258 
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assessment component, a social networking interface and teaching team contact details for on-259 
going support. In addition to reinforcement of face-to-face learning, this eLearning tool aims 260 
to facilitate ongoing and re-fresher training and act as a point of contact for troubleshooting 261 
and quality assurance issues. This blended learning approach (face-to-face programme 262 
supported by eLearning) aims to provide an effective and accessible form of MBW training to 263 
sites.  264 
 265 
Conclusions   266 
MBW to measure LCI is emerging as a promising outcome measure with potential for 267 
integration into routine clinical management of patients with CF and growing potential for use 268 
in bronchiectasis, asthma and COPD. In order for integration into clinical practice to be 269 
successful, training of the appropriate personnel in the technical aspects of set up, conducting 270 
the test, interpretation and quality assurance of results is essential. We propose that respiratory 271 
physiotherapists are ideally placed to undergo such training and become qualified to perform 272 
the MBW technique in response to expansions in service delivery. We have demonstrated the 273 
successful training and certification of clinical and research physiotherapists and encourage 274 
other respiratory physiotherapists to explore the area of MBW test training. 275 
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Appendix 1: Training Programme: Multiple Breath Washout Test using Modified 
InnocorTM device: Queen’s University Belfast & Belfast Health and Social Care Trust  
PROGRAMME 
Multiple Breath Washout (MBW) Test using Modified InnocorTM device: Queen’s University 
Belfast & Belfast Health and Social Care Trust 
Author: Katherine O’Neill, Prof. Judy Bradley, Prof. Stuart Elborn. 
INSTRUCTIONAL GOALS  
 
At the end of this course, you will: 
• Understand the principals underpinning MBW testing. 
• Be able to independently prepare the InnocorTM device and the testing room for procedure. 
• Be able to independently set up device and perform all calibration procedures as per SOP 
• Be able to maintain the set up to standard as per infection control guidelines in the SOP. 
• Know how to complete and maintain the InnocorTM Usage log and the MBW Procedure 
and Analysis Washout Sheets. 
• Know how to adequately explain and prepare patient for procedure. 
• Be able to successfully conduct MBW test on adults as per SOP. 
• Be able to recognize technically inadequate tests that may warrant an additional test. 
• Be able to export the test tracings from the InnocorTM device in preparation for analysis. 
 
 
 
 
NEEDS AND RESOURCES 
 
Required Background 
To successfully complete this course, you must; 
 
• Read the key references 
 Robinson, P.D., Goldman, M.D. & Gustafsson, P.M. 2009, "Inert gas washout: theoretical 
background and clinical utility in respiratory disease", Respiration, vol. 78, no. 3, pp. 339-
355.  
 Horsley, A. 2009, "Lung clearance index in the assessment of airways disease", 
Respiratory medicine, vol. 103, no. 6, pp. 793-799 
 
• Read the SOP 
 Multiple breath washout test using modified InnocorTM device SOP; Nick Bell; Clinical 
Research Fellow; UK Cystic Fibrosis Gene Therapy Consortium; 20th September 2010. 
 
Required Equipment 
To commence and successfully complete this course, you will need 
• InnocorTM in place with adaptations made as per SOP (see page appendix C SOP)  
• Supply of SF6 gas (NB: Wall bracket or cylinder trolley for size L cylinder required; flow 
head/regulator for size L cylinder required (ordered through BOC part number 850820) 
(see page 5 SOP) 
 
 
 
• Room set up for procedure (see page 5 SOP) 
• Flow past circuit and patient interface consumables in stock (see page 19 SOP) 
 
Required Materials 
To successfully complete this course, you will need; 
• Multiple breath washout test using modified InnocorTM device SOP; Nick Bell; Clinical 
Research Fellow; UK Cystic Fibrosis Gene Therapy Consortium; 20th September 2010. 
• MBW Procedure and Analysis Washout Sheets 
• Multiple Breath Washout Test using the Modified InnocorTM device ; LCI operator 
Qualification Assessment Form; Oct 2011 
• InnocorTM Instructions for Use Manual 
 
 
 
 
COURSE CONTENT 
 
TRAINING ITEMS 
1. Overview of references and SOP. 
2. Checklist of all equipment and consumables in place 
3. Set up room, equipment and patient interface 
 
4. Familiarisation with equipment 
a) InnocorTM  
b) InnocorTM menus 
c) Patient interface 
d) Flow past circuit 
e) Gas cylinder 
f) Room set up 
 
5. Practice with set up and calibration  
a) Flow meter linearization 
b) Flow meter calibration 
c) Flow gas delay calibration 
 
6. Preparing and explaining procedure to patients 
7. Concepts of washin; disconnection and washout (as per SOP).  
8. Observe a test *Volunteer needed* 
9. Supervised practice with patients / volunteers *Volunteer(s) needed* 
 
 
 
a) Including keeping the log and note keeping during the test. 
b) Troubleshooting: Awareness of reasons for invalid tests (technician related 
and patient related) and how to avoid. 
10. Infection control procedures  
a) Patient interface  
b) Room 
 
11. Accessing and downloading tracings; sending tracings to analyzer. 
12. Information obtained post analysis. 
 
 
Certification procedure (completed independent post programme) 
Trouble shooting on calibration and testing. 
Collection of 10 tests.  
9/10 technically acceptable tests required for certification. 
If <9/10 tests valid, submission of additional 5 tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2: Knowledge and Confidence Assessment Questionnaire_ Multiple Breath Washout 
Test using Modified InnocorTM device_Queen’s University Belfast & Belfast Health and Social 
Care Trust_Katherine O’Neill_March 2013 
 
Knowledge assessment questionnaire  
 
Multiple choice questions- Please choose one 
 
 
 
 
1. LCI is derived from  
 
a) Single breath washout test 
b) Multiple breath washout test 
c) Body plethysmography test 
d) Diffusion capacity test 
 
2. LCI is a measure of  
 
a) Airflow 
b) Perfusion 
c) Inflammation 
d) Gas mixing efficiency 
 
3. The upper limit of normal for LCI is 
 
a) 10 
b) 5.5 
c) 7.5 
d) 15.5 
 
4. LCI is calculated as 
 
a) The number of lung turnovers required to washout a tracer gas 
b) The concentration of tracer gas at functional residual capacity 
 
 
 
c) The mean concentration of C02 at end tidal volume 
d) The number of lung regions ventilated 
 
5. LCI is a measure most sensitive to 
 
a) Large airways dysfunction 
b) Small airways dysfunction 
c) Sp02 levels 
d) Airways inflammation 
 
6. LCI is a measure which is most informative in 
 
a) Patients with advanced disease 
b) Patients awaiting transplant 
c) Healthy individuals  
d) Children and patients with mild disease 
 
 
 
 
 
 
 
 
Confidence assessment questionnaire  
 
 
 
Please answer the following questions which relate to your confidence in MBW procedure 
to obtain LCI 
 
Rate your confidence performing calibration procedures for MBW testing before starting 
the training programme  
 
 
Rate your confidence performing calibration procedures for MBW testing on completion of 
the training programme 
 
 
 
              
              
Not confident   0 1 2 3 4 5 6 7 8 9 10 Very confident 
              
              
Not confident   0 1 2 3 4 5 6 7 8 9 10 Very confident 
 
 
 
Rate your confidence using equipment to perform MBW test before starting the training 
programme 
 
Rate your confidence using equipment to perform MBW test on completion of the training 
programme 
 
Rate your confidence on interpreting the LCI result from the results sheet before starting 
the training programme 
 
 
              
              
Not confident   0 1 2 3 4 5 6 7 8 9 10 Very confident 
              
              
Not confident   0 1 2 3 4 5 6 7 8 9 10 Very confident 
              
              
Not confident   0 1 2 3 4 5 6 7 8 9 10 Very confident 
 
 
 
 
Rate your confidence interpreting the LCI result from the results sheet on completion of 
the training programme 
Rate your confidence on maintenance of the MBW equipment before starting the training 
programme 
 
 
Rate your confidence maintenance of the MBW equipment on completion of the training 
programme 
 
              
              
Not confident   0 1 2 3 4 5 6 7 8 9 10 Very confident 
              
              
Not confident   0 1 2 3 4 5 6 7 8 9 10 Very confident 
              
              
Not confident   0 1 2 3 4 5 6 7 8 9 10 Very confident 
